Compare Novo Nordisk A/S (NVO) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Schlumberger NV — how do they compare? Novo Nordisk A/S trades at $46.23 (market cap $207.85B), while Schlumberger NV trades at $52.83 (market cap $79.67B). The key difference: Novo Nordisk A/S is far larger — about 2.6× Schlumberger NV's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | SLB | |
|---|---|---|
Market Cap | $207.85B | $79.67B |
Sector | Health | Energy |
52-Week High | $63.98 | $58.01 |
52-Week Low | $35.29 | $31.72 |
Enterprise Value | $222.55B | $88.40B |
Dividend Yield | 3.81% | 2.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
SLB trades at $53.20, up 5.28% over the past day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.55 versus $0.511 expected, driven by digital and production growth. Revenue for 2025 was $35.71 billion, with net income of $3.37 billion, though margins have compressed from prior years. The stock shows robust institutional support and positive media sentiment following upbeat results.
Outlook remains positive with a consensus price target of $63.00, implying 18% upside, supported by offshore and digital expansion. Risks include Middle East volatility and net debt concerns. The dividend yield is modest at around 1.1%, with the next payment scheduled for October 2026. Investors should weigh growth catalysts against regional and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
